J&J files suit against Amgen to protect Procrit sales

Share this article:
Johnson & Johnson has filed an antitrust lawsuit accusing rival Amgen of engaging in illegal sales practices to drive its best-selling drug Procrit (epoetin alfa) out of the market.
The lawsuit was filed in Federal District Court in Trenton, N.J.
"We believe the allegations in the complaint are without merit, and we plan to vigorously defend our position," Mary Klem, Amgen associate director, external communications, told MM&M.
The dispute involves Amgen's anti-anemia drug, Aranesp (darbepoetin alfa), which J&J's Ortho Biotech said now accounts for about two-thirds of sales to oncology clinics for products to aid red-blood cell growth.
Ortho Biotech claimed in the suit that Amgen penalizes oncology clinics by requiring they buy nearly all red blood-cell growth drugs from Amgen if the clinics want good deals on its two white blood-cell growth drugs, Neulasta (pegfilgrastim) and Neupogen (filgrastim).
Amgen has a near monopoly for the lifesaving white blood cell drugs, with 98 percent of clinic sales, Ortho Biotech said.
Failure to buy at least 75 percent of red blood cell growth drugs from Amgen means that a clinic will have to buy Neulasta and Neupogen at prices that exceed government reimbursement, the lawsuit said.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.